Growth Metrics

Lifecore Biomedical (LFCR) Income towards Parent Company: 2009-2025

Historic Income towards Parent Company for Lifecore Biomedical (LFCR) over the last 17 years, with May 2025 value amounting to -$38.7 million.

  • Lifecore Biomedical's Income towards Parent Company fell 38333.33% to -$1.1 million in Q2 2025 from the same period last year, while for May 2025 it was -$38.7 million, marking a year-over-year decrease of 1543.59%. This contributed to the annual value of -$38.7 million for FY2025, which is 1543.59% down from last year.
  • Per Lifecore Biomedical's latest filing, its Income towards Parent Company stood at -$38.7 million for FY2025, which was down 1,543.59% from $2.7 million recorded in FY2024.
  • In the past 5 years, Lifecore Biomedical's Income towards Parent Company registered a high of $2.7 million during FY2024, and its lowest value of -$101.9 million during FY2022.
  • Its 3-year average for Income towards Parent Company is -$23.8 million, with a median of -$35.3 million in 2023.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first skyrocketed by 107.59% in 2024, then crashed by 1,543.59% in 2025.
  • MRY analysis of 5 years shows Lifecore Biomedical's Income towards Parent Company stood at -$10.3 million in 2021, then tumbled by 890.66% to -$101.9 million in 2022, then skyrocketed by 65.34% to -$35.3 million in 2023, then surged by 107.59% to $2.7 million in 2024, then tumbled by 1,543.59% to -$38.7 million in 2025.
  • Its Income towards Parent Company was -$38.7 million in FY2025, compared to $2.7 million in FY2024 and -$35.3 million in FY2023.